Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer

Fig. 3

Construction and analysis of genome-wide DNA methylation signature. A. Partial likelihood deviance of host genes revealed by the LASSO-Cox regression model. The red dots represented the partial likelihood of deviance values, the gray lines represented the standard error (SE), the two vertical dotted lines on the left and right represented optimal values by minimum criteria and 1-SE criteria, respectively. 1-SE criteria was used to select host genes in model. B. LASSO coefficient profiles of the survival-related host genes. C. The clinicopathological characteristics of patients in different risk signature subgroups. The number in the row of group indicated the PFS of patient. D. Kaplan-Meier analysis of patients with high-risk signature and low-risk signature for PFS. E. Kaplan-Meier analysis of patients with high-risk signature and low-risk signature for OS

Back to article page